Crowley John F's Form 4 filing
Amicus Therapeutics, Inc.FOLD · filed Feb 5, 2024
- Accession no.
- 0000950170-24-011433
- Filed
- Feb 5, 2024
- Trade date
- Feb 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $399.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crowley John FCIK 0001400973 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Common Stock | SSaleDisposed | −31,614 | $12.62F1 | −$398,968.68 | 750,838 | Direct | |
| Feb 1, 2024 | Common Stock | FTax withholdingDisposed | −21,596 | $12.67 | −$273,621.32 | 729,242 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.44 to $12.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
All sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2023.